Efficacy of first-line bleomycin, etoposide, and cisplatin chemotherapy for peripheral blood stem cell mobilization in patients with germ cell cancer

International Journal of Clinical Oncology

Volumn 3, Issue 3, 1998, Pages 147-151

  Yamada, Yuji ^a   Hara, Isao ^a   Gohji, Kazuo ^a   Nakamura, Ichiro ^a   Oka, Yasuhiko ^a   Arakawa, Soichi ^a   Kamidono, Sadao ^a  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apheresis; Chemotherapy; Germ cell cancer; Peripheral blood stem cell

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE;

ADULT; APHERESIS; ARTICLE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DRUG EFFICACY; GERM CELL TUMOR; HUMAN; LEUKOCYTE COUNT; MALE; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL; STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION; TESTIS CANCER; THROMBOCYTE COUNT;

EID: 0031844478     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02489907     Document Type: Article

References (20)

1. Pizzocaro G, Piva L, Salvioni R, Zanoni F, Milani A. Cisplatin, etoposide, bleomycin first-line therapy and early resection of residual tumor in far-advanced germinal testis cancer. Cancer 1985;56:2411-2415.
2. Nichols CR, Williams SD, Loehrer PJ, Greco FA, Crawford ED, Weetlaufer J, Miller ME, Bartolucci A, Schacter L, Einhorn LH. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 1991;9:1163-1172.
3. Einhorn LH, Weathers T, Loehrer P. Second line chemotherapy with vinblastine, ifosfamide, and cisplatin after initial chemotherapy with cisplatin, VP-16, and bleomycin (PVPB) in disseminated germ cell tumors (GCT): long term follow up. Proc Am Soc Clin Oncol 1992;11:196 (abstr).
4. Motzer RJ, Geller NL, Tan CC, Herr H, Morse M, Fair W, Sheinfeld J, Sogani P, Russo P, Bosl GJ. Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979-1989). Cancer 1991;67:1305-1310.
5. Nichols CR, Andersen J, Lazarus HM, Fisher H, Greer J, Stadtmauer EA, Loehrer PJ, Trump DL. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol. J Clin Oncol 1992;10:558-563.
6. Motzer RJ, Mazumdar M, Bosl GJ, Bajorin DF, Amsterdam A, Vlamis V. High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity. J Clin Oncol 1996;14:1098-1105.
7. Henon PR, Liang H, Beck-Wirth G, Eisemann JC, Lepers M, Wunder E, Kandel G. Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. Bone Marrow Transplant 1992;9:285-291.
8. Bokemeyer C, Schmoll HJ. Treatment of advanced germ cell tumours by dose intensified chemotherapy with haematopoietic growth factors or peripheral blood stem cells (PBSC). Eur Urol 1993;23:223-230.
9. Schwella N, Beyer J, Schwaner I, Heuft HG, Rick O, Huhn D, Serke S, Siegert W. Impact of preleukapheresis cell counts on collection results and correlation of progenitor-cell dose with engraftment after high-dose chemotherapy in patients with germ cell cancer. J Clin Oncol 1996;14: 1114-1121.
10. Margolin K, Doroshow JH, Ahn C, Hamasaki V, Leong L, Morgan R, Raschko J, Shibata S, Solmo G, Tetef M. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support. J Clin Oncol 1996;14:2631-2637.
11. Nakagawa S, Sugimoto K, Mikami K, Watanabe H, Sonoda Y, Abe T, Fujii H. Successful collection of peripheral blood stem cells mobilized by high-dose etoposide for patients with chemotherapy-resistant and/or poor prognostic testicular cancer. Jpn J Urol 1994;85:571-578.
12. Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K, Gooley T, Demirer T, Schiffman, Weaver C. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995;13: 2547-2555.
13. Richman CM, Weiner RS, Yankee RA. Increase in circulating stem cells following chemotherapy in man. Blood 1976;47:1031-1039.
14. Liu KY, Akashi K, Harada M, Takamatsu Y, Niho Y. Kinetics of circulating haematopoietic progenitors during chemotherapy-induced mobilization with or without granulocyte colony-stimulating factor. Br J Haematol 1993;84:31-38.
15. Kohno A, Takeyama K, Narabayashi M, Okamoto R, Adachi I, Tobinai K, Shimoyama M. Low-dose granulocyte colony-stimulating factor enables the efficient collection of peripheral blood stem cells after disease-oriented, conventional-dose chemotherapy for breast cancer, malignant lymphoma and germ cell tumor. Bone Marrow Transplant 1995;15:49-54.
16. Brugger W, Bross K, Frisch J, Dern P, Weber B, Mertelsmann R, Kanz L. Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin. Blood 1992;79:1193-1200.
17. Bensinger W, Singer J, Appelbaum F, Lilleby K, Rowley S, Clarke E, Clift R, Hansen J, Shields T. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 1993;81:3158-3163.
18. Duhrsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988;72:2074-2081.
19. Sheridan WP, Begley CG, Juttner CA, Szer J, To LB, Macher D, McGrath KM, Morstyn G, Fox RM. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992;339:640-644.
20. Sheridan WP, Begley CG, To LB, Grigg A, Szer J, Maher D, Green MD, Rowlings PA, McGrath KM, Cebon J. Phase II study of autologous filgrastim (G-CSF)-mobilized peripheral blood progenitor cells to restore hematopoiesis after high-dose chemotherapy for lymphoid malignancies. Bone Marrow Transplant 1994;14:105-111.